| HIBMC (2001-2008, R) | Pts with HCC <5 cm | 105 | 52.8 - 76 Gy in 4 - 20 f | Not reported | 92.5% at 3 y | 49.1% at 5 y | 8 G3 acute toxicities 1 G3 late skin**** |
| HIBMC (2001-2009, R) | Pts with IVCTT | 16 (13 pts treated with protons, 3 pts treated with carbon ions) | 66 Gy in 10 f = 4pts 60 Gy in 10 f = 4 pts 76 Gy in 20 f = 3 pts 76 Gy in 38 f = 1 pt 56 Gy in 8 f = 1 pt | Not reported | 100 % at last FUP**** | OS = 61.1% at 1 y OS = 36.7% at 3 y**** | 1 G2 acute hepatic toxicity 2 G2 acute dermatitis 1 G2 late hepatic toxicity (resolved with conservative management)**** |
| HIBMC (2001-2009, R) | Review of all patients treatedin the observation period | 242 | Various schedules = 76 Gy in 38 f, 56 Gy in 8 f, 60 Gy in 10 f, 76 Gy in 20 f, 66 Gy in 10 f, 80 Gy in 20 f, 84 Gy in 24 f, 52.8 Gy dpf in 4 f | 31 m | 90.2% at 5 y for all pts 84.1% at 5 y for T ≥ 5 < 10 cm | 38% at 5 y for all pts 67.6% at 5 y for BCLC stage 0-A pts 30.6% at 5 y for BCLC stage C pts | ≥G3 late toxicities in 8 pts 1 G4 dermatitis 4 G3 dermatitis 1 G3 biloma 1 G3 panniculitis 1 G3 GI ulcer 1RILD 8 G2 rib fractures |
| NCCHE (1999-2003, P) | CP A-B, max T size = 10 cm, Multinodular HCCs elegible if 1) a single CTV could be created or 2) lesions far from target controlled by other therapies | 30 | 76 Gy in 20 f | 31 m (16 - 54) | LPFR = 96 at 2y | OS = 62% at 3 y DFS 16% at 3 y | 8 PHI (4 deaths without recurrence) 1 skin erosion, 1 painful subcutaneous fibrosis |
| NCCHE (1999-2007, R) | Update of the previous report including patients treated off-protocol | 60 | Various schedules = 76 Gy in 20 f, 60 Gy in 10 f, 65 Gy in 26 f | 43 m (25 - 92) | LPFS at 3 y = 90% (all pts) LPFS at 5 y = 86% (all pts) LPFS at 3 y for pts receiving 76 Gy vs those receiving 62.5 Gy = 97% vs 56% (P = 0.005) 61% radiological CR 1 to 50 m after PT | OS at 3 y = 56% (all pts) OS at 5 y = 25% (all pts) | PHI in 11 pts, all with ICG R15 > 20%, 7 deaths (5 without recurrence) 3 ≥ G2 GI toxicities, 1duodenitis 1colon ulcer, 1esophagitis |
| LLUMC (1998-2006, P) | Inclusion criteria: <3 lesions, no extra-hepatic spread, no tense ascites | 76 | 63 Gy in 15 f | NA | 80% at 5 y | PFS for patients within Milan criteria = 60% at 3y PFS for patients outside Milan criteria = 20% at 3y 70% OS for transplanted pts | 5 G2 GI toxicities No RILD |
| NCC (2008-2011, R) | Pts with PVTT | 27 | Various schedules = 50 - 66 Gy in 20-22 f | 13.2 m (2.4 - 51.7) | LPFS at 2 y = 61.9% | Median OS = 13 m | No ≥ G3 acute and late toxicities 14.5% 1 point increase in CP score 7% late G2 GI toxicities |
| MGH (2006-2009, P) | Pilot study of respiratory-gated PT for liver tumors | 15 (HCC = 11)***** | Various schedules = 45 - 75 Gy in 15 f | 69 m for survivors | 100% at last FUP | OS at 3 y = 33% | 2 G3 hyperblirubinemia 1 G3 gastrointestinal bleed 1 G5 gastrointestinal perforation |